Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank_resource:DB00361_DB01319_nanopub.RATUgDxCErl8u2k5iExRWS3m9F2GTKa0mDBUusiEvDrEA#assertion>. }
Showing items 1 to 6 of
6
with 100 items per page.
- drugbank_resource:DB00361_DB01319 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB00361_DB01319 label "DDI between Vinorelbine and Fosamprenavir - Fosamprenavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Vinorelbine by decreasing its metabolism. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Fosamprenavir is initiated, discontinued or dose changed. [drugbank_resource:DB00361_DB01319]" assertion.
- drugbank_resource:DB00361_DB01319 identifier "drugbank_resource:DB00361_DB01319" assertion.
- drugbank_resource:DB00361_DB01319 title "DDI between Vinorelbine and Fosamprenavir - Fosamprenavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Vinorelbine by decreasing its metabolism. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Fosamprenavir is initiated, discontinued or dose changed." assertion.
- drugbank:DB01319 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00361_DB01319 assertion.
- drugbank:DB00361 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00361_DB01319 assertion.